Imigran

Sumatriptan succinate, the active ingredient in Imigran, is a Triptan presented as a tablet for oral use. It treats acute migraine attacks with or without aura in adults. GNH USA supplies Imigran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran (sumatriptan succinate) is indicated for acute migraine treatment, acting on the serotonergic pathway.

Migraine with aura: provides rapid relief of headache and associated symptoms. Migraine without aura: reduces pain intensity and duration. Acute migraine attacks (any type): alleviates headache, nausea, photophobia and phonophobia.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Dizziness or light‑headedness - Fatigue or drowsiness - Nausea or abdominal pain

Serious or Rare Side Effects: - Serotonin syndrome, especially with serotonergic drugs - Coronary artery vasospasm leading to chest pain - Severe allergic reaction such as anaphylaxis - Stroke or transient ischemic attack - Persistent hypertension

Before using Imigran, consider the following precautions: - Cardiovascular disease: avoid use due to risk of vasoconstriction. - Uncontrolled hypertension: contraindicated. - History of stroke or transient ischemic attack: use with caution. - Concomitant serotonergic agents: monitor for serotonin syndrome. - Pregnancy: safety not established; consult a physician. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Imigran may interact with several medicines.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Ergot derivatives: additive vasoconstriction may cause severe cardiovascular events. - Other triptans: concurrent use can increase vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: monitor for signs of serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels.